Moon Surgical’s Maestro: What the AI Actually Does
Moon Surgical is a French-American company that builds a robotic assistant for laparoscopic surgery.
Its platform, Maestro, holds the camera and instruments steady so the operating team can work with fewer hands.
The company now describes Maestro as an AI platform, which makes it worth separating what is cleared from what is claimed.
What Moon Surgical Maestro Is
Maestro is a robotic surgical assistant that augments the precision and control of laparoscopic surgery.
It does not replace the surgeon or the existing laparoscopic setup.
It is designed to work in any laparoscopy and in any operating room, according to the company.
The FDA clearance for the base Maestro system dates to June 2024.
What ScoPilot Does
ScoPilot is the AI feature that lets the laparoscope follow a chosen instrument tip.
The surgeon no longer needs to take a hand off an instrument to adjust the field of view.
The FDA cleared ScoPilot on March 18, 2025, with the original Maestro system and an earlier camera-holding robot as predicate devices.
Moon Surgical describes it as the first AI application to run intraoperatively on a commercially available surgical robot with NVIDIA Holoscan, which is a company claim.
No peer-reviewed outcomes study of ScoPilot was found.
What Software Version 2.7 Adds
On June 9, 2026, Moon Surgical announced Maestro Software Version 2.7.
The update adds automated setup, which optimizes platform positioning based on surgeon preferences, operating room layout, technique, and patient anatomy.
It also adds an enhanced ScoPilot trained on newly observed instruments and clinical configurations.
The third addition is automated operative reporting and coding through a third-party AI company, Uncovr.
The company says these features draw on a dataset of more than 3,000 procedures, which has not been independently verified.
How the Update Path Works
On July 2, 2025, the FDA cleared connectivity for Maestro and a Predetermined Change Control Plan for ScoPilot.
That plan allows Moon Surgical to release updated versions of the AI within agreed limits without a new submission for each change.
Connectivity also supports Maestro Insights, a cloud platform that tracks utilization and scheduling across sites.
Early Clinical Use of Automated Reporting
On June 30, 2026, Moon Surgical and Uncovr reported the first 20 patients whose surgeries used automated operative reporting on Maestro.
Moon Surgical describes this as the first third-party AI solution used on the platform in clinical practice.
Twenty cases are a deployment milestone and not a performance study.
The KARL STORZ Collaboration
On July 22, 2026, Moon Surgical and KARL STORZ announced a strategic commercial collaboration.
The agreement pairs Maestro with KARL STORZ 3D visualization and instrumentation.
The stated goal is to make advanced laparoscopic surgery easier to adopt across hospitals, ambulatory surgery centers, and rural sites.
What Is Proven and What Is Not
The base system, ScoPilot, connectivity, and the change control plan are cleared and documented.
Claims about efficiency, consistency, and scalability come from company releases.
Independent clinical evidence for the AI features has not been published.
Compare Maestro with every other tracked system in the NextInSurgery Surgical AI and Robotics Database.
Read more claim-by-claim analysis in The 2026 Surgical Technology Intelligence Report.
